{"id":70611,"date":"2026-04-13T18:38:49","date_gmt":"2026-04-13T13:08:49","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70611"},"modified":"2026-04-13T18:38:53","modified_gmt":"2026-04-13T13:08:53","slug":"balaxi-pharmaceuticals-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/","title":{"rendered":"BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>BALAXI PHARMACEUTICALS (BALAXI) Q4 FY26 results are scheduled for May 15, 2026, when the company&#8217;s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 520 as of April 2026 \u2014 down -30% from its 52-week high of Rs 780 \u2014 the stock has been under pressure alongside its peers in the Pharma Exports \/ Emerging Markets sector. This Q4 results preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook.<\/p><p>BALAXI PHARMACEUTICALS&#8217;s Q4 FY26 earnings will be watched for signals on the company&#8217;s +15% exports YoY trajectory, and whether operating metrics are recovering toward normalised levels. This article provides a structured preview based on analyst consensus data and publicly available financial information.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get free investment predictions on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#BALAXI_PHARMACEUTICALS_Q4_Results_2026_Date\" title=\"BALAXI PHARMACEUTICALS Q4 Results 2026 Date\">BALAXI PHARMACEUTICALS Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Why_Q4_FY26_Matters\" title=\"Why Q4 FY26 Matters\">Why Q4 FY26 Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#BALAXI_PHARMACEUTICALS_Q4_FY26_Earnings_Estimates\" title=\"BALAXI PHARMACEUTICALS Q4 FY26 Earnings Estimates\">BALAXI PHARMACEUTICALS Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#5_Key_Factors_Driving_BALAXI_PHARMACEUTICALS_Q4_FY26_Performance\" title=\"5 Key Factors Driving BALAXI PHARMACEUTICALS Q4 FY26 Performance\">5 Key Factors Driving BALAXI PHARMACEUTICALS Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#1_Africa_and_CIS_Export_Growth\" title=\"1. Africa and CIS Export Growth\">1. Africa and CIS Export Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#2_Branded_Generics_Premium_Margins\" title=\"2. Branded Generics Premium Margins\">2. Branded Generics Premium Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#3_Regulatory_Dossier_Paipeline\" title=\"3. Regulatory Dossier Paipeline\">3. Regulatory Dossier Paipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#4_Currency_and_Political_Risk_Management\" title=\"4. Currency and Political Risk Management\">4. Currency and Political Risk Management<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#5_Product_Portfolio_Depth\" title=\"5. Product Portfolio Depth\">5. Product Portfolio Depth<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#5_Risks_to_Watch_in_BALAXI_PHARMACEUTICALS_Q4_FY26\" title=\"5 Risks to Watch in BALAXI PHARMACEUTICALS Q4 FY26\">5 Risks to Watch in BALAXI PHARMACEUTICALS Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Risk_1_Currency_Depreciation_in_Target_Markets\" title=\"Risk 1: Currency Depreciation in Target Markets\">Risk 1: Currency Depreciation in Target Markets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Risk_2_Competition_from_Indian_Generic_Majors\" title=\"Risk 2: Competition from Indian Generic Majors\">Risk 2: Competition from Indian Generic Majors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Risk_3_Regulatory_Approval_Delays\" title=\"Risk 3: Regulatory Approval Delays\">Risk 3: Regulatory Approval Delays<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Risk_4_Payment_Collection_Risk\" title=\"Risk 4: Payment Collection Risk\">Risk 4: Payment Collection Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Risk_5_Supply_Chain_Disruptions\" title=\"Risk 5: Supply Chain Disruptions\">Risk 5: Supply Chain Disruptions<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#BALAXI_PHARMACEUTICALS_Share_Price_and_Analyst_Ratings\" title=\"BALAXI PHARMACEUTICALS Share Price and Analyst Ratings\">BALAXI PHARMACEUTICALS Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_When_is_BALAXI_PHARMACEUTICALS_Q4_results_2026_date\" title=\"Q: When is BALAXI PHARMACEUTICALS Q4 results 2026 date?\">Q: When is BALAXI PHARMACEUTICALS Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_What_is_BALAXI_PHARMACEUTICALS_Q4_FY26_revenue_estimate\" title=\"Q: What is BALAXI PHARMACEUTICALS Q4 FY26 revenue estimate?\">Q: What is BALAXI PHARMACEUTICALS Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_What_is_BALAXI_PHARMACEUTICALS_Q4_FY26_PAT_estimate\" title=\"Q: What is BALAXI PHARMACEUTICALS Q4 FY26 PAT estimate?\">Q: What is BALAXI PHARMACEUTICALS Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_Will_BALAXI_PHARMACEUTICALS_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will BALAXI PHARMACEUTICALS declare a dividend in Q4 FY26?\">Q: Will BALAXI PHARMACEUTICALS declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_What_is_BALAXI_PHARMACEUTICALS_current_share_price\" title=\"Q: What is BALAXI PHARMACEUTICALS current share price?\">Q: What is BALAXI PHARMACEUTICALS current share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_What_were_BALAXI_PHARMACEUTICALS_Q3_FY26_results\" title=\"Q: What were BALAXI PHARMACEUTICALS Q3 FY26 results?\">Q: What were BALAXI PHARMACEUTICALS Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"Q: When do TCS and Infosys announce Q4 results 2026?\">Q: When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Q_Is_BALAXI_PHARMACEUTICALS_a_good_investment_ahead_of_Q4_results\" title=\"Q: Is BALAXI PHARMACEUTICALS a good investment ahead of Q4 results?\">Q: Is BALAXI PHARMACEUTICALS a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BALAXI_PHARMACEUTICALS_Q4_Results_2026_Date\"><\/span><strong>BALAXI PHARMACEUTICALS Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The BALAXI PHARMACEUTICALS Q4 FY26 results date is May 15, 2026. The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter ended March 31, 2026, and the full year FY2025-26.<\/p><p>Here is a broader view of the Q4 FY26 results calendar for reference:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Key Metric<\/strong><\/td><\/tr><tr><td>[object Object]<\/td><td>April 9, 2026 (Declared)<\/td><td>FY27 revenue guidance, deal TCV<\/td><\/tr><tr><td>[object Object]<\/td><td>April 23, 2026<\/td><td>CC growth guidance for FY27<\/td><\/tr><tr><td>Bharat Electronics (BEL)<\/td><td>May 8, 2026<\/td><td>Order book execution, EBITDA margin<\/td><\/tr><tr><td>Bharat Forge<\/td><td>May 10, 2026<\/td><td>Global CV + defence execution<\/td><\/tr><tr><td>BALAXI PHARMACEUTICALS<\/td><td>May 15, 2026<\/td><td>See estimates below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Q4_FY26_Matters\"><\/span><strong>Why Q4 FY26 Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 (January-March) is the final quarter of FY26, making it the most important earnings event of the year. Beyond the quarterly numbers, investors will receive: full-year FY26 financial summary, management commentary on FY27 business outlook, and the final dividend recommendation for FY26 shareholders.<\/p><p>For BALAXI PHARMACEUTICALS specifically, Q4 FY26 captures the peak season dynamics of the Pharma Exports \/ Emerging Markets sector. Management&#8217;s commentary on FY27 demand visibility will set the investment narrative for the next 12 months.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BALAXI_PHARMACEUTICALS_Q4_FY26_Earnings_Estimates\"><\/span><strong>BALAXI PHARMACEUTICALS Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670.jpeg\" alt=\"BALAXI PHARMACEUTICALS Q4 FY26 analyst consensus estimates \u2014 Revenue, PAT, Margin | univest.in\" class=\"wp-image-70614\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium research on Univest<\/strong><\/a>.<\/p><p>Based on publicly available analyst consensus, here are the Q4 FY26 estimates for BALAXI PHARMACEUTICALS:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Trend<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 185 Cr<\/td><td>Rs 162 Cr<\/td><td>QoQ expected improvement<\/td><\/tr><tr><td>Net Profit (PAT)<\/td><td>Rs 22 Cr<\/td><td>Rs 18 Cr<\/td><td>Normalisation expected<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 14%<\/td><td>Q3 FY26 margin<\/td><td>QoQ trend<\/td><\/tr><tr><td>Volume \/ Growth Driver<\/td><td>+15% exports YoY<\/td><td>Prior quarter<\/td><td>YoY<\/td><\/tr><tr><td>Dividend (Expected)<\/td><td>Rs 1 (expected)<\/td><td>FY26 interim dividends<\/td><td>Final dividend<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <strong>BALAXI PHARMACEUTICALS<\/strong> live fundamentals on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time Q4 result alerts and analyst updates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_Driving_BALAXI_PHARMACEUTICALS_Q4_FY26_Performance\"><\/span><strong>5 Key Factors Driving BALAXI PHARMACEUTICALS Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Africa_and_CIS_Export_Growth\"><\/span><strong>1. Africa and CIS Export Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Balaxi Pharmaceuticals focuses on exporting branded generic formulations to Africa, the CIS (Commonwealth of Independent States), and Southeast Asia. These markets have growing middle-class populations and increasing healthcare access funding.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Branded_Generics_Premium_Margins\"><\/span><strong>2. Branded Generics Premium Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Selling branded (rather than pure commodity) generics in export markets commands 30-40% price premium over unbranded alternatives. Balaxi&#8217;s brand investment in target markets builds pricing power over time.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Regulatory_Dossier_Paipeline\"><\/span><strong>3. Regulatory Dossier Paipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Filing regulatory dossiers (for product approvals) in new markets builds the future revenue pipeline. New dossier filings and approvals in Q4 would indicate geographic expansion pace.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Currency_and_Political_Risk_Management\"><\/span><strong>4. Currency and Political Risk Management<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Export to Africa and CIS involves currency volatility and political risk. Balaxi&#8217;s ability to manage currency hedging and select stable markets determines export revenue quality.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Product_Portfolio_Depth\"><\/span><strong>5. Product Portfolio Depth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Broader therapeutic area coverage (cardiovascular, anti-infective, vitamins) in target markets increases wallet share from distributor partners. New product additions in Q4 would be positive.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_BALAXI_PHARMACEUTICALS_Q4_FY26\"><\/span><strong>5 Risks to Watch in BALAXI PHARMACEUTICALS Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Currency_Depreciation_in_Target_Markets\"><\/span><strong>Risk 1: Currency Depreciation in Target Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>African and CIS currencies can depreciate significantly against USD, reducing USD-equivalent revenue.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Competition_from_Indian_Generic_Majors\"><\/span><strong>Risk 2: Competition from Indian Generic Majors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma, Cipla, and Dr Reddy&#8217;s all export to Africa and emerging markets with larger product portfolios and established relationships.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_3_Regulatory_Approval_Delays\"><\/span><strong>Risk 3: Regulatory Approval Delays<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Product registration in Africa can take 2-4 years. Delays in approvals push out revenue from new markets.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_4_Payment_Collection_Risk\"><\/span><strong>Risk 4: Payment Collection Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Emerging market healthcare distributors can have extended payment cycles, increasing receivable risk.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_5_Supply_Chain_Disruptions\"><\/span><strong>Risk 5: Supply Chain Disruptions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Export logistics to remote African markets face supply chain complexity and cost.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BALAXI_PHARMACEUTICALS_Share_Price_and_Analyst_Ratings\"><\/span><strong>BALAXI PHARMACEUTICALS Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-1024x536.jpg\" alt=\"BALAXI PHARMACEUTICALS share price and analyst ratings \u2014 Q4 FY26 preview\" class=\"wp-image-70616\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 520<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 780<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 460<\/td><\/tr><tr><td>1-Year Return<\/td><td>-30%<\/td><\/tr><tr><td>Market Capitalisation<\/td><td>Rs 720 Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharma Exports \/ Emerging Markets<\/td><\/tr><tr><td>NSE Ticker<\/td><td>BALAXI<\/td><\/tr><\/tbody><\/table><\/figure><p>Analyst ratings and target prices based on publicly available brokerage research:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Investment Thesis<\/strong><\/td><\/tr><tr><td>Anand Rathi<\/td><td>BUY<\/td><td>Rs 660<\/td><td>Africa pharma market growing 12% annually<\/td><\/tr><tr><td>Choice Broking<\/td><td>ADD<\/td><td>Rs 620<\/td><td>Branded generic premium sustainable<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Balaxi Pharmaceuticals Q4 FY26 will reflect emerging market pharmaceutical demand trends. Revenue above Rs 185 crore with EBITDA margin above 13% would be a beat. The Africa and CIS export growth is the core thesis.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_is_BALAXI_PHARMACEUTICALS_Q4_results_2026_date\"><\/span><strong>Q: When is BALAXI PHARMACEUTICALS Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>BALAXI PHARMACEUTICALS Q4 FY26 results date is May 15, 2026. The board of directors will meet on this date to approve the quarterly and full-year FY26 financial results and consider recommending a final dividend.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_BALAXI_PHARMACEUTICALS_Q4_FY26_revenue_estimate\"><\/span><strong>Q: What is BALAXI PHARMACEUTICALS Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for BALAXI PHARMACEUTICALS Q4 FY26 revenue is Rs 185 Cr. Q3 FY26 actual revenue was Rs 162 Cr. Actual Q4 results may vary based on operating conditions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_BALAXI_PHARMACEUTICALS_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is BALAXI PHARMACEUTICALS Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus estimate for BALAXI PHARMACEUTICALS Q4 FY26 net profit (PAT) is Rs 22 Cr. Q3 FY26 actual PAT was Rs 18 Cr. Estimates are indicative and not guaranteed.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Will_BALAXI_PHARMACEUTICALS_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will BALAXI PHARMACEUTICALS declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>BALAXI PHARMACEUTICALS is expected to declare Rs 1 (expected) for FY26, subject to board approval at the May 15, 2026 board meeting and subsequent shareholder approval at the AGM.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_BALAXI_PHARMACEUTICALS_current_share_price\"><\/span><strong>Q: What is BALAXI PHARMACEUTICALS current share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>BALAXI PHARMACEUTICALS is trading at Rs 520 as of April 2026, with a 52-week range of Rs 460 to Rs 780. The 1-year return is -30%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_were_BALAXI_PHARMACEUTICALS_Q3_FY26_results\"><\/span><strong>Q: What were BALAXI PHARMACEUTICALS Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, BALAXI PHARMACEUTICALS reported revenue of Rs 162 Cr and net profit (PAT) of Rs 18 Cr. The Q4 FY26 results on May 15, 2026 will provide a comparison to assess sequential and year-on-year trends.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>Q: When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026 (see the BALAXI PHARMACEUTICALS earnings calendar table above). Infosys is scheduled to declare results on April 23, 2026. Both are covered in detail on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_BALAXI_PHARMACEUTICALS_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Q: Is BALAXI PHARMACEUTICALS a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. BALAXI PHARMACEUTICALS trades at Rs 520 with a 52-week range of Rs 460 to Rs 780. Analyst consensus targets and the Q4 FY26 estimates suggest monitoring the results date closely. Consult a SEBI-registered financial advisor for personalised investment guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/techno-electric-and-engineering-q4-results-2026\">Techno Electric &amp; Engineering Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/jbm-auto-q4-results-2026\">JBM Auto Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/varroc-engineering-q4-results-2026\">Varroc Engineering Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/hitachi-energy-india-q4-results-2026\">Hitachi Energy India Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cg-power-and-industrial-solutions-q4-results-2026\">CG Power and Industrial Solutions Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>BALAXI PHARMACEUTICALS (BALAXI) Q4 FY26 results are scheduled for May 15, 2026, when the company&#8217;s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 520 as of April 2026 \u2014 down -30% from its 52-week high of Rs 780 \u2014 the stock has been under pressure alongside its<\/p>\n","protected":false},"author":28,"featured_media":70620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-70611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776085755:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-670.jpeg\";a:2:{s:2:\"id\";i:70614;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183503\/image-670.jpeg\";a:2:{s:2:\"id\";i:70614;s:11:\"source_type\";s:13:\"media-library\";}s:106:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings.jpg\";a:2:{s:2:\"id\";i:70616;s:11:\"source_type\";s:13:\"media-library\";}s:115:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-1024x536.jpg\";a:2:{s:2:\"id\";i:70616;s:11:\"source_type\";s:13:\"media-library\";}s:138:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings.jpg\";a:2:{s:2:\"id\";i:70616;s:11:\"source_type\";s:13:\"media-library\";}s:147:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183624\/BALAXI-PHARMACEUTICALS-share-price-and-analyst-ratings-1024x536.jpg\";a:2:{s:2:\"id\";i:70616;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_description":["BALAXI PHARMACEUTICALS Q4 results date is May 15, 2026. Revenue estimate Rs 185 Cr, PAT estimate Rs 22 Cr. Key factors, risks, analyst ratings and BALAXI PHARMACEUTICALS share price outlook."],"rank_math_title":["BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["BALAXI PHARMACEUTICALS Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["70620"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8000"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13183727\/BALAXI-PHARMACEUTICALS-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70611"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70611\/revisions"}],"predecessor-version":[{"id":70622,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70611\/revisions\/70622"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70620"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}